Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

5F-BZO-POXIZID

Synthetic cannabinoid of the OXIZID class, a CB1 and CB2 agonist, with no human data at all.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₀H₂₀FN₃O₂

CAS 3047777-35-2

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
353.40 g/mol

Updated on

In plain terms

5F-BZO-POXIZID is a synthetic cannabinoid made in a clandestine laboratory, with no link to hemp. It was first detected in powders and vaping liquids seized in China, as a variant of a research molecule called MDA-19. Its effects in humans have never been studied and no safety data exist for this substance.

Receptors and activity

Target network

CB1Agonistno measured value
  • Activates

The lower the cited value, the closer the target sits to 5F-BZO-POXIZID: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 5F-BZO-POXIZID.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Agonistno measured value cited
  2. CB2Partial agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

5F-BZO-POXIZID (5F-MDA-19) belongs to the OXIZID class, isatin acylhydrazones whose emergence responds to the generic bans that targeted the indole and indazole scaffolds (Deventer et al. 2022). Liu et al. (2022) described it for the first time, in powders and vaping liquids seized in China, with no earlier chemical or pharmacological data. In a β-arrestin 2 recruitment assay, the OXIZIDs tested are full agonists at CB1 and partial agonists at CB2; fluorination of the pentyl analogue does not increase activation (Deventer et al. 2022). Patel et al. (2024) place the series behind earlier generations of synthetic cannabinoids, in both potency and efficacy. No clinical study, no controlled trial and no published case documents this molecule in humans.

Key sources.

History

Source
A wholly synthetic molecule, absent from hemp and from any known living organism. The 5-fluoropentyl derivative of BZO-POXIZID (the hexyl chain of MDA-19 is replaced by a 5-fluoropentyl chain), it was first detected by Liu et al. (2022) in powders and vaping liquids seized in China after the generic legislation of July 2021; according to Deventer et al. (2022), the emergence of OXIZIDs is a response to this legislation.

Origin

Laboratory synthesis

No biosynthetic pathway: the molecule does not exist in living organisms. It is an N-alkylated isatin acylhydrazone (oxindol-3-ylidene benzohydrazide) bearing a 5-fluoropentyl chain, described here by its chemical class only.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

oxoindole (OXIZID)

Verification

Checked on 20 October 2026; some points still await human review.

Wikipedia (English)

No dedicated article.

References

  1. Liu et al. · Drug Test Anal 2022 (new tab)PMID 34694738
  2. Deventer et al. · Drug Test Anal 2022 (new tab)PMID 35560866
  3. Patel et al. · Eur J Pharmacol 2024 (new tab)PMID 38561104
  4. Lee et al. · Clin Chem 2022 (new tab)PMID 36175111
  5. Watanabe et al. · J Anal Toxicol 2023 (new tab)PMID 36857377
  6. Xiang et al. · Metabolites 2023 (new tab)PMID 37110234
  7. Palamar et al. · J Anal Toxicol 2024 (new tab)PMID 37952092
  8. Sekuła et al. · J Am Soc Mass Spectrom 2025 (new tab)PMID 40193255

Identifiers

Names

IUPAC name
N-[1-(5-fluoropentyl)-2-hydroxyindol-3-yl]iminobenzamide
Other names
5F-MDA-19 · 5-fluoro BZO-POXIZID

Identifiers

Formula
C₂₀H₂₀FN₃O₂
CAS
3047777-35-2
PubChem CID
162368405(new tab)
InChIKey
NUMFJISMJAWIOG-UHFFFAOYSA-N
SMILES
C1=CC=C(C=C1)C(=O)N=NC2=C(N(C3=CC=CC=C32)CCCCCF)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.